The graph illustrates the steps and the components of a pharmacokinetic analysis of DCE-MRI. There should be
- decently acquired Dynamic MR dataset (with sufficiently temporal resolution),
- Vascular Input Function (or AIF) in a nearby and feeding vessel of the investigated tumor and
- a suitable pharmacokinetic model.
The outcome of such mathematical operation will be following parameters:
- transfer constant (ktrans),
- Fraction Volume of EES (ve), and
- Fractional Volume of Blood Plasma in Tissue(vp) as well as the
- Goodness of Fit (r2), a method to justify the mathematical fitting.
In terms of practicality a DCE-MRI analysis software should be able to assist users pick up AIF with ease within a dataset and provide a variety of PK models to cope with acquired dataset.
tWAN Biotech’s competences in DCE-MRI stems from the representation of MIStar software and serving our users in leading hospitals. tWAN Biotech regards acquiring high quality dataset for pharmacokinetic analysis as our responsibility and we scan with our clients to optimize both scan and injection protocols. On demand our expert is glad to assist our clients accomplish pilot study.
We have extensive experience in applying DCE-MRI to cancers in following organs/body regions:
- Brain (GBM, Brain Metastasis)
- Oral Cavity
- Liver (HCC)
- Soft Tissue